HC Wainwright Cuts CASI Pharmaceuticals (NASDAQ:CASI) Price Target to $4.00
CASI Pharmaceuticals (NASDAQ:CASI – Free Report) had its price target lowered by HC Wainwright from $6.00 to $4.00 in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings […]
CASI Pharmaceuticals (NASDAQ:CASI – Free Report) had its price target lowered by HC Wainwright from $6.00 to $4.00 in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q1 2025 earnings at ($0.61) EPS, Q2 2025 earnings […]
